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ABSTRACT
Myelodysplastic Syndromes (MDS) are clonal neoplasms where stem/progenitor 
cells endowed with self-renewal and capable of perpetuating the disease have 
been demonstrated. It is known that oxygen tension plays a key role in driving 
normal hematopoiesis and that hematopoietic stem cells are maintained in hypoxic 
areas of the bone marrow (BM). Hypoxia could also regulate leukemic/dysplastic 
hematopoiesis. We evaluated the stem cell potential of MDS cells derived from the 
BM of 39 MDS patients and selected under severe hypoxia. MDS cells rescued from 
hypoxia-incubated cultures were subjected to stem and progenitor cell assays in vitro, 
as well as to hematopoietic reconstitution assay in NOD-SCID mice. Incubation in 
severe hypoxia of cells explanted from MDS patients selected a cell subset endowed 
with stem cell potential, as determined in vitro. This occurred only from the BM 
of patients classified as IPSS low/INT-1 risk. Transplantation into NOD-SCID mice 
confirmed using an in vivo model that severe hypoxia selects a cell subset endowed 
with stem cell potential from bone marrow mononuclear cells (BMMC). derived 
from patients belonging to the IPSS low/int-1 risk group. Data here reported show 
that cells endowed with stem cell potential and capable of adapting to hypoxia and 
escaping hypoxia-induced apoptosis exist within MDS cell populations. 
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INTRODUCTION
Myelodysplastic syndromes (MDS) have been 
shown to comprise stem/progenitor cells endowed with 
self-renewal and capable of perpetuating the disease [1]. 
The cytogenetic and genetic abnormalities found in MDS 
are accompanied by a number of changes of immune 
system and bone marrow (BM) microenvironment [2, 3], 
all defects which could affect the biology of MDS stem/
progenitor cells and contribute to the heterogeneity of this 
group of diseases [4]. How stem cell regulation is altered 
in MDS and how many residual normal hematopoietic 
stem cells (HSC) are present in the various stages of these 
diseases is still not clear [5].
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Oxygen tension plays a key role in normal 
hematopoietic development and stem cells niches, where 
HSC are hosted, are placed in the most hypoxic areas 
of BM [6]. In particular, severe hypoxia modulates the 
balance between generation of progenitors and HSC 
maintenance in favour of the latter, and resistance or 
sensitivity to severe hypoxia defines hierarchical levels 
within normal hematopoietic populations [7–9]. Oxygen 
tension is likely to control also MDS hematopoiesis. For 
instance, MDS cells cultured in 1–3% O2 were shown to 
exhibit an increased colony formation efficiency [10]. 
The capacity of adaptation of MDS stem/progenitor cells 
to hypoxia, as well as the majority of human tumor stem 
cells [11], can be crucial not only for the maintenance 
of disease, but also its progression, as hypoxia induces 
genomic instability [12]. 
 In the study reported here, primary human BM 
mononuclear cells (BMMC) from MDS cases were 
cultured in hypoxia to test whether it were possible to 
select neoplastic stem/progenitor cells under conditions 
favouring HSC maintenance. Cells were obtained 
from different MDS subtypes, heterogeneous for their 
cytogenetic and overall clinical IPSS risk score, in order 
to verify the occurrence of phenotype-specific differences 
of stem cell potential. MDS cells rescued from hypoxia-
incubated cultures were subjected to colony formation 
ability (CFA) and culture repopulation ability (CRA) 
assay, the latter being a stem cell assay in vitro, as well as 
to repopulation assay in NOD-SCID mice [13, 14]. The 
results obtained suggest that, via incubation in hypoxia, 
it is possible to select relatively primitive HSC from IPSS 
lower-risk MDS patients.
RESULTS
Effects of hypoxia on the maintenance of the 
stem cell potential of MDS cells 
The stem cell potential of BMMC obtained from 39 
MDS cases and incubated at 0.1% O2 or under standard 
conditions (“normoxia”) was estimated by the CRA assay 
(Figure 1). Cells were incubated in primary liquid cultures 
(LC1) at 0.1% O2 or in normoxia and then transferred to 
secondary cultures (LC2) always incubated in normoxia. 
The stem cell potential at the end of “selective” LC1 was 
estimated by measuring the output of “growth-permissive” 
LC2. Figure 2 shows examples of the three observed 
different outcomes. Viable cell number in LC1 decreased 
of at least one log at day 10–13 of culture in 0.1% O2, 
while it increased in normoxia, as expected (Figure 2A–
2C, left panels). MDS IPSS high risk (RAEB-2, case #21) 
and IPSS low/int-1 risk (RCMD, case #7) cases did not 
repopulate LC2 efficiently (middle and right panels), 
irrespective of whether LC1 had been incubated in 0.1% 
O2 or in air (Figure 2A, 2B). On the contrary, an IPSS 
low/int-1 risk case classified as RCMD (case #4) was 
capable of a significant LC2 repopulation, but only when 
cells were incubated in low oxygen (Figure 2C, middle 
and right panels). LC2 repopulation results relative to the 
whole group of patients studied, reported in Table 1, can 
be summarized as follows:
1)  IPSS high risk - BMMC → LC1 in 0.1% O2 or in 
air → no LC2 repopulation (9/9 cases);
2)  IPSS low risk - BMMC → LC1 in 0.1% O2 or in 
air → no LC2 repopulation (16/30 cases);
3)  IPSS low risk - BMMC → LC1 in 0.1% O2 or in 
air → LC2 repopulation (14/30 cases) only with 
cells from LC1 in 0.1% O2 (See Supplementary 
Figure 1A–1E). The peak values of LC2 
repopulation achieved and the day of peak are 
reported in Table 2. The IPSS risk categories are 
defined in the Materials & Methods section. 
CFA assays were carried out in parallel to CRA 
assays. GM, E and, in one case, GEM colonies were 
formed. Colonies were generated from the low-risk 
cases endowed with CRA, but not from high-risk cases 
or from the low-risk cases which did not show CRA 
(data not shown). Taken together, the data indicated that 
hematopoietic potential was maintained only by MDS 
cells derived from patients classified as IPSS low/INT-1 
risk and only following incubation in 0.1% O2. 
Effects of hypoxia on the expression of cell 
surface antigens in MDS cells.
The expression of surface markers CD34, CD38, 
CD117, CD133 in BMMC from all 39 MDS cases studied 
was evaluated before and after incubation in 0.1% O2 or 
in normoxia (Figure 3). The percentage of viable cells as 
well as the relative percentage of viable CD34-positive 
cells decreased with respect to time 0 following either 
incubation condition (Figure 4). A significant difference 
of marker expression with respect to time 0 was observed 
only in cells incubated at 0.1% O2 and only for CD38, 
which was about 50% reduced. This reduction is consistent 
with the selection of relatively immature hematopoietic 
progenitor cells.
Cytogenetic analysis
BMMC derived from 5 MDS patients (see Table 
1 for complete data) with pre-identified chromosomal 
aberrations were subjected to FISH analysis at time 
0 of culture and after incubation in hypoxia. The cases 
analyzed were: one RCMD with 7q- (case #18), one 
RCMD with 20q- (case #20), one RA with –Y (case #27), 
all classified as IPSS low/int-1 cases; two RAEB-2 (#28 
and #32), which presented a complex karyotype, classified 
as IPSS high risk cases. 
In all cases we observed the maintenance of equal 
percentages of cells with chromosomal aberrations after 
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hypoxia incubation respect to time 0. In particular, in 
the RCMD case #20, characterized by 7q deletion, the 
percentage of cells with chromosomal aberration was 
68% at time 0 and 65% following incubation in hypoxia. 
Identical percentages were obtained by FISH analysis 
of RCMD case #20. In the #27 RA case, characterized 
by deletion of Y, –Y cells were 65,6% at baseline and 
82,4% after incubation in hypoxia; this case was one of 
the 14 characterized by CRA, while at the peak of LC2 
repopulation (day 15 of incubation), FISH analysis showed 
a reduction of percentage of cells with chromosomal 
aberration (68,8%) respect to cell population after hypoxia 
incubation, as if normal cells were overgrowing. Among 
the RAEB-2 cases analysed, #28 and #32 showed a 
percentage of cells characterized by complex karyotype 
of respectively 66% and 60% at time 0 and 70% and 62% 
after incubation in hypoxia. We suppose that the cells 
with normal karyotype may belong to the normal residual 
hematopoietic progenitor cell population. Following 
incubation in hypoxia, cells from all cases maintained the 
initial chromosomal aberrations, indicating suggesting that 
cells resistant to/selected in hypoxia belong to the original 
cell clone.
Evaluation of genes commonly mutated in MDS
We performed mutation analysis of 8 cases (seven 
classified as IPSS low/int-1 risk and one as IPSS high 
risk) by NGS at time 0, but we could not demonstrate a 
specific correlation between baseline number and type of 
mutations and CRA after incubation (data no shown). 
In vivo engraftment of MDS cells incubated in 
hypoxia
Figure 5 shows the in vivo repopulation ability, 
measured in peripheral blood (PB) and BM of recipient 
mice (A, C, E and B, D, F, respectively), of cells derived 
from 3 different IPSS low/int-1 MDS cases. BMMC 
rescued from day-10 cultures incubated at 0.1% O2 
were injected intravenously into NOD/SCID mice. 
A 5q- syndrome case (#38) showed a peak of human 
CD45-positive cells, in either PB or BM, at day 42 after 
transplantation (A, B); a second 5q- syndrome case (#37) 
failed engraftment (C, D); the CRDM case (#39) showed 
a peak of human CD45-positive cells, in either PB or BM, 
at day 71 after transplantation (E, F). We could not detect 
Figure 1: Schematic representation of CRA assay and its cognate MRA assay. The CRA assay is a short-term HSC assay in 
vitro cognate to the MRA assay in vivo. At the end of their experimental manipulation (such as a drug treatment or, as in the experiments 
reported here, an incubation under selective conditions), cells are subjected to an “expansion phase” where the stem cell potential of HSC 
is exploited, carried out by either transplantation into syngeneic mice (Marrow Repopulation Ability) or transfer into a growth-permissive, 
non-selective (secondary–LC2) culture (Culture Repopulation Ability). Repopulation ability is quantified by counting the total number of 
cells in the bone marrow of transplantation-recipient mice or LC2, respectively (see Materials & Methods for details).
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human cells in the spleens. We performed in parallel the 
CRA assay: case #38 (5q- syndrome) was capable of a 
significant LC2 repopulation too, peaking at day 17 
with 2,76 × 105 cells/ml; the second 5q- syndrome case 
(#37), that failed engraftment in mice, did not show any 
repopulating ability in hypoxia selected cells; CRA assay 
performed for CRDM case (#39) showed the repopulating 
capacity of hypoxia selected cells, peaking at day 19 with 
4 × 105 cells/ml (see Tables 1 and 2 for complete data).
DISCUSSION 
Clonal evolution of MDS increases the level of 
heterogeneity of these diseases and renders a homogenous 
approach to therapy more difficult. We learned that 
there are linear and branching clonal evolution paths 
that are patient-specific [15]. These dynamic processes 
most probably deeply affect the stem cell potential 
of individual MDS cases. The isolation of primary 
MDS stem cells based on biological properties, or by 
exploiting their capacity to propagate and proliferate in 
hypoxic environment, could lead to the characterization 
of the “stemness” level of each case and thereby to an 
improvement of their therapeutic targeting. 
Our study showed that incubation in severe hypoxia 
of cells explanted from MDS patients selects a cell subset 
capable to escape hypoxia-induced apoptosis and endowed 
with stem cell potential, as determined by repopulation 
ability in vitro (CRA assay). FISH analysis showed that 
these cells maintain chromosomal markers typical of the 
original MDS clone. 
Cell selection in hypoxia was possible only in a 
defined subgroup of MDS cases, i.e. derived from patients 
belonging to the IPSS low/int-1 risk group. Nevertheless, 
Figure 2: Effects of incubation in hypoxia or normoxia on total cell number or stem cell potential of MDS cells. BMMC 
were explanted from three patients taken as examples of the three different case subsets considered (see Tables 1 and 2). The three patients 
were classified as: (A) high risk IPSS RAEB-2, (B) low/inte1 IPSS risk RCMD, (C) low/int-1 IPSS risk RA. Cells were incubated in low 
oxygen or in air (LC1) for 10 days (left panels) and then transferred to secondary cultures incubated in air (LC2) for the measure of stem 
cell potential of LC1 cells by CRA assay (cells from normoxic LC1, middle panels; cells from hypoxic LC1, right panels).
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Table 1: Overall patient characteristics
Case # Age Sex WHO IPSS IPSS-R BM Blast% Karyotype CRA
1 71 M RCMD int-1 int 0 7q-[15/20] no
2 88 M RAEB-2 high very high 20 11q-[18/20] no
3 74 F RCMD low very low 0 normal yes
4 48 M RCMD int-1 int 0 complex yes
5 65 M RCMD low very low 0 normal yes
6 56 F RAEB-1 int-1 int 2 normal no
7 65 F RCMD low very low 0 normal no
8 81 F RCMD int-1 int 0 +8[17/20] no
9 71 F RCMD int-1 int 0 +8[13/20] no
10 78 M RCMD low int 0 inv14 no
11 73 F RA int-1 int 0 t(7;12) yes
12 67 F RAEB-2 high very high 19 complex no
13 83 F RAEB-1 high high 8 normal no
14 78 M RCMD int-1 Int 4 normal no
15 88 M RA low low 0 20q-[17/20] yes
16 70 F RAEB-1 int-1 high 8 5q-[16/20] no
17 76 M RAEB-1 int-1 int 5 normal no
18 56 F RCMD int-1 Int 0 7q-[18/20] no
19 80 F RCMD low very low 0 normal yes
20 71 M RCMD int-1 Int 0 20q-[14/20] yes
21 72 M RAEB-2 high high 17 normal no
22 70 F RAEB-2 high very high 20 normal no
23 83 F RAEB-2 int-2 high 16 normal no
24 89 F RA low low 0 normal yes
25 70 M RAEB-1 int-1 int 8 normal yes
26 76 M RA int-1 int 5 +8[14/20] no
27 82 M RA low very low 0 -Y[16/20] yes
28 83 F RAEB-2 int-2 high 18 complex no
29 60 M RCMD low very low 0 normal yes
30 63 M RA int-1 low 0 +8[16/20] yes
31 81 M RAEB-2 high high 15 +8[18/20] no
32 79 M RAEB-2 high very high 20 complex no
33 72 M RCMD int-1 int 0 7q-[15/20] no
34 78 F 5q- Syndrome low very low 0 5q-[18/20] no
35 77 F 5q- Syndrome int-1 very low 0 5q-[17/20] no
36 69 M RCMD low very low 0 normal no
37 71 M 5q- Syndrome low very low 0 5q-[19/20] no
38 83 F 5q- Syndrome int-1 low 0 5q-[18/20] yes
39 79 M RCMD low very low 0 normal yes
Among the IPSS low/int-1 risk group, 14/39 (36%) cases (dark grey) after incubation in low oxygen exhibited stem cell 
potential determined by culture repopulation ability (CRA) assay, while 16/30 cases did not show any CRA (light grey). 
Neither the cases classified as IPSS high/int-2 risk cases exhibited CRA (white). 
Oncotarget10566www.impactjournals.com/oncotarget
only 14/30 cases of this group were found endowed 
with repopulation ability. No chromosomal abnormality 
or somatic mutation detected was found to correlate 
with the absence or the presence of such an ability. To 
select under hypoxia cells exhibiting stem cell potential 
was impossible for IPSS high-risk cases; we reckon that 
hypoxia may have a non-permissive effect on dysplastic 
blasts. Blast morphology may indeed correspond to a 
hierarchical structure of cell population where stem cell 
potential is located within a relatively less immature cell 
Table 2: LC2 repopulation data relative to the MDS cases endowed with CRA
Case# WHO IPSS IPSS-R BM Blast % Karyotype
Day of peak 
of LC2 
repopulation
Value of LC2 
repopulation at peak 
(cell × 10–3/ml)
3 RCMD low very low 0 normal 21 306
4 RCMD int-1 int 0 complex 17 550
5 RCMD low very low 0 normal 19 355
11 RA int-1 int 0 t(7;12) 19 498
15 RA low low 0 20q[10/20] 17 190
19 RCMD low very low 0 normal 25 275
20 RCMD int-1 int 0 20q[10/20] 15 208
24 RA low low 0 normal 17 210
25 RAEB-1 int-1 int 8 normal 17 250
27 RA low very low 0 –Y[17/20] 15 491
29 RCMD low very low 0 normal 15 445
30 RA int-1 low 0 +8[16/20] 21 244
38 5q-Syndrome Int-1 low 0 5q-[18/20] 17 276
39 RCMD low very low 0 normal 19 407
The incubation day and the value of peak of LC2 repopulation for the 14/39 CRA-positive cases are reported.
Figure 3: Effects of incubation in hypoxia or normoxia on the expression of CD38, CD117, CD133 in CD34-positive 
cells. BMMC explanted from all patients listed in Table 1 were subjected to flow cytometry to measure the expression of CD38, CD117 
and CD133 in CD34-positive cells at time 0 and following a 10-day incubation in hypoxia or normoxia. The significance of differences was 
calculated by the Student t tests for paired samples; * = P < 0.0027.
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phenotype, which is thereby hypoxia-sensitive instead of 
being hypoxia-resistant.
The MDS cases exhibiting measurable stem cell 
potential showed an apparently wide range of variations 
as for the time (15–25 days) and level (208–550 × 10–3 
cells/ml of culture) of peak of LC2 repopulation. Peak 
time and repopulation level appeared unrelated. Wide 
differences among different cell populations with respect 
to these parameters have been observed in several studies 
[16–19]. A recent publication, with the exclusive analysis 
of a subset of IPSS low/int-1 risk MDS (5q- cases), 
indicated the in vivo existence of rare (multipotent) MDS 
stem cells and defined their hierarchical relationship to 
lineage-restricted MDS progenitor cells [20]. These 
results are consistent with what we observed here by 
CRA assay in 14 IPSS low/int-1 risk MDS cases. It is 
worth noting that flow cytometry analysis revealed 
that, when incubated in hypoxia, CD34-positive MDS 
cells underwent a significant reduction of CD38 co-
expression with respect to normoxia-incubated controls. 
This reduction is well in keeping with the selection 
of relatively less mature hematopoietic progenitor 
cells, which are those able to adapt to the hypoxic 
environment. 
Transplantation into NOD-SCID mice confirmed 
using an in vivo model that severe hypoxia selects a cell 
subset endowed with stem cell potential from BMMC 
derived from patients belonging to the IPSS low/int-1 risk 
Figure 4: Effects of incubation in hypoxia or normoxia on the viability and the expression of CD34 in BMMC. BMMC 
explanted from all patients listed in Table 1 were incubated with 7-Amino-Actinomycin D (7-AAD)- Viability Dye, at time 0 and following 
a 10–13 day incubation in hypoxia or normoxia, in order to identify the percentage o viable cells (A). Relative CD34 expression of viable 
cells was evaluated, and normalized per experimental point (B).
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group. However, these experiments could not confirm that 
engraftment was determined by MDS stem cells. Rather, 
it is possible that normal hematopoietic progenitor cell 
population, endowed as expected with stem cell potential 
and capacity of adaptation to hypoxia, did engraft, 
generating the CD45-positive human cells detected in 
PB and BM of recipient mice. It is of interest that this 
was possible only in IPSS low/int-1 risk cases, but not 
in the high risk patients. The kinetics of hematopoietic 
reconstitution observed in PB and BM of transplanted 
mice were different. This may reflect the selection of cell 
subsets of different hierarchical level within the stem cell 
compartment, due to the patient-specific clonal structure 
of disease. The evaluation of MDS clone burden in a 
higher number of cases, as well as the detection of the 
original mutation in the MDS cells expanded following 
incubation in hypoxia could shed more light onto the 
variables affecting the growth of hypoxia-selected 
primitive cells.
If in vivo experiments will confirm that MDS 
stem cells of IPSS lower-risk MDS cases are capable 
of surviving under a metabolic pressure matching that 
of the hypoxic niche hosting normal HSC, one may 
conceive the use of hypoxia-activated drugs (such as the 
phosphate ester PR104, which is able to induce DNA 
cross-linking at low oxygen tension) to specifically 




BM samples were obtained from 39 patients diagnosed 
with different subtypes of MDS at the Haematology Unit, 
AOUC, Florence, Italy, after signed informed consent in 
accordance with the Declaration of Helsinki. MDS patient 
characteristics are reported in Table 1: median age, 74 years 
(56–89), M/F ratio, 21/18. In accordance to WHO criteria, 
patients were classified as: RA (6), RCMD (16), RAEB-
1 (5) and RAEB-2 (8) and 5q- syndrome (4); 22 patients 
exhibited cytogenetic abnormalities and 16 showed a normal 
karyotype. According to the International Prognostic Scoring 
System (IPSS), 30 patients were classified as low/int-1 risk, 
and 9 as int-2/high risk. 
Cells and culture conditions 
BMMC were separated by standard density gradient 
centrifugation (Lympholyte-H; Cedarlane Laboratories 
Ltd; Burlington, Canada). Cells were cultured in RPMI 
1640 medium supplemented with 20% fetal bovine serum, 
50 units/ml penicillin, 50 mg/ml streptomycin (all from 
EuroClone; Paington, U.K.) 50 ng/ml FLT-3, ligand, 20 
ng/ml TPO, 50 ng/ml SCF and 0.5 ng/ml IL-3 (all from 
PeproTech; London, U.K.). Cells were incubated under 
standard conditions (21% O2) or in atmosphere at 0.1 
Figure 5: Kinetics of engraftment of BMMC derived from MDS patients in NOD/SCID mice. BMMC explanted from 
patients classified as IPSS low/int-1 risk were incubated in low oxygen (LC1) for 10 days, and then intravenously injected into eight-week-
old NOD/SCID beta 2 null mice, previously subjected to a single-dose 250cGy total body irradiation. Mice transplanted with human MDS 
cells were termed Hu-mu. The percentage of human CD45+ cells was determined by flow cytometry in PB or BM samples obtained from 
mice sequentially after transplantation. Human CD45+ cells were detected in mice transplanted with cells derived from a 5q- syndrome (A, 
B) or a CRDM (E, F) patient, but not in the case of a different 5q- syndrome (C, D).
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% O2, in a Concept 400 anaerobic incubator (Ruskinn 
Technology Ltd.; Bridgend, U.K.).
CRA assay 
The CRA assay is a non-clonogenic assay developed 
to estimate in vitro the stem cell potential of cells endowed 
with marrow repopulation ability in vivo (Figure 1). This 
assay estimates the power of normal hematopoietic [7–9] 
or leukemic [13, 15–18] cells, freshly rescued from donor 
or subjected to an experimental treatment in vitro, to 
expand in treatment-free, growth-permissive cultures. 
The CRA assay represents a simple and economic method 
to detect in vitro short term-repopulating hematopoietic 
stem cells (STR-HSC). In the study reported here, cells 
incubated in hypoxia for 10 days (“selection” primary 
liquid culture - LC1) were transferred to fresh medium 
supplemented with 50 ng/ml SCF, 100 ng/ml G-CSF, 
20 ng/ml IL-6 and 10 ng/ml IL-3 (“expansion“ secondary 
liquid culture - LC2) and incubated in normoxia. To 
measure LC2 repopulation, cells were counted daily by 
trypan blue exclusion.
CFA assay
Cells from liquid cultures incubated in hypoxia for 
10 days were replated (120.000 cells/ml) in semisolid 
medium (MethoCult H4100; Stem Cell Technologies; 
Vancouver, Canada) and incubated for 14 days in the 
presence of the same cytokine cocktails used for the LC2 
of CRA assay (see above). GEM, GM and E colonies were 
scored.
Cytogenetic and FISH analysis 
Cytogenetic and FISH studies were performed 
according to the standard methods used in our laboratory. 
Cultures were incubated for 48 hours at 37° C. G-banding 
was performed on slides kept at 60° C overnight and 
then stained with Wright’s solution. A minimum of 20 
metaphases were analyzed and described according 
to the International System for Human Cytogenetic 
Nomenclature 2013 [22]. Fluorescent in situ hybridization 
(FISH) was performed with α-satellite DNA probes for 
chromosomes 8 and Y (CEP8 and CEPY; Vysis; Abbott 
Park, IL, U.S.A.) and locus-specific probes for 7q31 and 
5q31, 20q12 (LSI D7S522/CEP7, LSI EGR1 and LSI 
D20S108; Vysis). At least 200 nuclei were analyzed; we 
considered that there was a chromosomal gain when the 
percentage of cells with trisomy was more than 5% and a 
chromosomal loss when more than 10% of cells presented 
the anomaly.
NGS methodology
We performed mutation analysis by NGS of 8 cases 
included in the study. SureDesing (Agilent Technologies; 
Santa Clara, CA, U.S.A.) was used to design a custom 
enrichment of the candidate genes: ASXL1, EZH2, TP53, 
SF3B1, U2AF1, SRSF2, TET2, DNMT3A, ETV6, RUNX1, 
NPM1, FLT3, CBL, SETBP1, CSF3R, CEBPA, IDH1, 
IDH2, JAK2, MPL, CARL, NRAS. Genes were selected 
after a manually curated literature screening of the most 
commonly mutated genes in MDS. Library preparation 
was performed using the HaloPlex target enrichment 
protocol (Agilent Technologies). The genomic DNA 
input for amplicon library preparation was 225 ng for 
each sample according to manufacturer’s instructions. All 
sample libraries were equimolarly pooled and sequenced 
on the MiSeq Sequencer (Illumina; San Diego, CA, 
U.S.A.) with a default 150 bp paired-end reads protocol, 
according to the manufacturer’s instructions.
Flow cytometry
BMMC at time 0 and after 10–13 days of incubation 
in hypoxia or normoxia were washed and suspended in 100 
ul of BD Stain Buffer (BD Biosciences; Franklin Lakes, 
NJ, U.S.A.), according to the manufacturer’s instructions. 
Cells were incubated with 7-Amino-Actinomycin D (7-
AAD)- Viability Dye (Beckam Coulter; Brea, CA, U.S.A.) 
allowing discrimination of viable from non viable cells, 
and then incubated with monoclonal antibodies directed 
to surface proteins: allophycocyanin (APC)-conjugated 
human CD133 (Miltenyi Biotec; Bergisch Gladbach, 
Germany), phycoerythrin (PE)-conjugated human 
CD117 (clone M-A712; BD Biosciences), PE(CY7)-
conjugated human CD38 (clone HIT-2; BD Biosciences), 
fluorescein (FITC)-conjugated human CD34 (clone 
8G12; BD Biosciences), APC(H7)-conjugated human 
CD45 (clone 2D1; BD Bosciences). Mouse-derived cells 
after xenotransplantation were incubated with peridinin-
chlorophyll (PerCP)-conjugated murine CD45 (clone 30-
F11; BD Biociences). Approximately 20000 events were 
collected for each sample using a FACSCanto analyzer 
(BD Biosciences) and data were processed using BD 
FacsDiva software. 
In vivo experiments
All in vivo experiments were performed at the 
Laboratory of Genetic Engineering for the Production 
of Animal Models (LIGeMA) at the Animal Facility of 
Università degli Studi di Firenze. Eight-week-old NOD/
SCID beta 2 null mice were subjected to total body 
irradiation with a single 250cGy dose 24 hours before 
transplantation of human cells. Patient-derived BMMC 
rescued from hypoxia-incubated cultures were resuspended 
at 1 × 106 cells/100 ul final concentration and then injected 
via the tail vein. Every two weeks from transplant, blood 
was drawn from the retro-orbital plexus and collected into 
EDTA-containing tubes, red blood cells were haemolysed, 
and mononuclear cells washed with PBS. At the scheduled 
end of experiment or when the mice were moribund, 
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femora, tibiae and spleens were collected. Cells were 
flushed from femora and tibiae using 23G needles. Spleen 
was minced and passed through 70 μm filters. Marrow 
and spleen cells were washed in haemolytic buffer and 
resuspended in PBS. The presence of CD45+ human cells 
in PB, BM and spleen of transplanted mice was evaluated 
by flow cytometry. Survival of mice for at least 28 days 
after transplantation was considered and indicator of 
successful engraftment, together with the presence of 
≥0.2% of human CD45+ cells in marrow or spleen [23].
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